KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativaProbabilità implicita attualebefore April 2027 81%In testa tra 6 esiti
Qualita del mercato
34 / 100
Bassa qualitàVolume 24h
5 €
Liquidità
3,1K €
Liquidità mediaBid / Ask
60.0% / 69.0%
Spread
9.0 pt
Spread ampioDati di mercato
Aggiornato 13 minuti fa
24 mar 26, 14:001 nov 26, 5:00
Trend
Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria
Esito scelto
before November69%
Trend del volume
$62 lug20g di dati27 lug
Mercati Correlati
Testosterone unscheduled/rescheduled more permissively in US by end of 2028?
510,9 €Sì: 17.8%MANIFOLD MARKETS
MANIFOLD MARKETS2026 Ebola epidemic deaths?
499,9 €<250: 0.2%MANIFOLD MARKETS
MANIFOLD MARKETSWill there be a cure for schizophrenia before 2032?
439,2 €Sì: 11.8%MANIFOLD MARKETS
MANIFOLD MARKETS
Hantavirus vaccine in 2026?
146,4 €Sì: 6%
POLYMARKET
POLYMARKET
Will there be a year without polio before 2030?
0 €Sì: 11%KALSHI
KALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?
0 €before September: 15%KALSHI
KALSHIAttivi in questi argomenti
Notizie Correlate
Crypto is the canary in the coal mine for the quantum computing threat, experts sayCoindesk
Galaxy Digital opens $5M fund for Bitcoin quantum security researchCrypto News
Claude's Fable 5 just solved an 87-year-old math problem, and it matters for bitcoinCoindesk
Google DeepMind, Isomorphic Labs Unveil AI-Powered Bioresilience PlanBlockchain.News
NVIDIA's Ising Decoder Slashes Color Code Errors 300xBlockchain.News
NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.NewsRegole
If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.